{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.458","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.46","upperLimit":"41.58","value":"35.9"},{"groupId":"OG001","lowerLimit":"27.67","upperLimit":"38.66","value":"33.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"301"},{"groupId":"OG001","value":"297"}],"units":"Participants"}],"description":"Overall response rate (ORR) is the best response of CR or PR as classified by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST, v1.1) guidelines. CR is defined as the disappearance of all target and non-target lesions, normalization of tumor marker level of non-target lesions, and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 millimeter (mm). PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were treated with Pemetrexed plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for three 21-day cycles, followed by a 3-5 week \"Recovery Period,\" then treated with consolidation chemotherapy with pemetrexed (\"Consolidation Phase\") for up to four 21-day cycles\n\nConcurrent Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle for 3 cycles. Cisplatin: 75 mg/m\\^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gy per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.\n\nConsolidation Phase:\n\nPemetrexed: 500 mg/m\\^2, IV on Day 1 of each 21-day cycle up to 4 cycles","id":"OG000","title":"Arm A: Pemetrexed + Cisplatin and TRT"},{"description":"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (\"Concurrent Phase\") for two 28-day cycles, followed by a 3-5 week \"Recovery Period,\" then received consolidation treatment with cytotoxic chemotherapy of choice (\"Consolidation Phase\") for up to 2 cycles\n\nConcurrent Phase:\n\nEtoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m\\^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m\\^2, IV on Days1, 8, 29, and 36\n\nConsolidation Phase options:\n\nOption 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m\\^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m\\^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m\\^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22","id":"OG001","title":"Arm B: Etoposide + Cisplatin and TRT"}],"paramType":"NUMBER","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline to Measured Progressive Disease (Up to 7 Months)","title":"Objective Response Rate (Complete Response [CR] + Partial Response [PR])","type":"SECONDARY","unitOfMeasure":"percentage of participants"}